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Abstract
Studies from our laboratory have shown that the folate-dependent enzyme, thymidylate synthase (TS), functions as an RNA binding
protein. There is evidence that TS, in addition to interacting with its own TS mRNA, forms a ribonucleoprotein complex with a number of
other cellular mRNAs, including those corresponding to the p53 tumor suppressor gene and the myc family of transcription factors. Using
both in vitro and in vivo model systems, we have demonstrated that the functional consequence of binding of TS protein to its own cognate
mRNA, as well as binding of TS to the p53 mRNA, is translational repression. Herein, we review current work on the translational
autoregulatory control of TS expression and discuss the molecular elements that are required for the TS protein–TS mRNA interaction. TS
may play a critical role in regulating the cell cycle and the process of apoptosis through its regulatory effects on expression of p53 and
perhaps other cell cycle related proteins. Finally, the ability of TS to function as a translational regulator may have important consequences
with regard to the development of cellular resistance to various anticancer drugs. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Control of eukaryotic gene expression is regulated at
several levels, including gene amplification, transcription,
splicing, nucleocytoplasmic transport, mRNA stability, trans-
lation, and post-translational modification and/or protein
processing. During the last several years, it has become
increasingly clear that translational control represents an
important process for regulating protein synthesis [1–4].
This mechanism is based on the central concept that cellular
gene expression is controlled by the efficiency of translation
of a given mRNA, in the absence of a corresponding change
in steady-state mRNA levels.
The ability to control protein synthesis by regulating the
translational efficiency of a given mRNA provides several
advantages to an organism. Translational control is an
energy-efficient process to control the expression of a given
protein. Using this mechanism, a given cell can respond
rapidly to exposure to various genotoxic and/or cytotoxic
stresses as well as to changes in the extracellular environ-
ment. It serves as a fine-tuning mechanism to ensure the
precise and desired level of a given cellular protein. To do so,
it works in close concert with other regulatory mechanisms
including transcription, post-transcription, and post-trans-
lation. Moreover, a significant lag-time, which is normally
required for signaling of various processes within the
nucleus including gene amplification, activation of tran-
scription, RNA processing, and nucleocytoplasmic transport
of RNA, is effectively bypassed, thereby allowing for rapid
changes in protein synthesis to be effected. As this process
represents the last step in protein synthesis, the overall
metabolic and energy requirements are minimized to a
significant extent. One further advantage of this control
pathway is that it is readily reversible. Once the cellular
requirements have been sufficiently met, protein synthesis
can be quickly restored to basal levels.
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Control of the cell cycle is a highly ordered process, and it
is regulated by the expression of certain critical checkpoint
proteins. Translational control of these proteins ensures and
maintains the ordered nature of the cell cycle that is neces-
sary for normal cell division to occur. It is, therefore, not
surprising that several cell cycle-related mRNAs have been
identified whose expressions are specifically regulated at the
translation level [4].
The present review focuses on translational control of the
folate-dependent enzyme thymidylate synthase (TS). We
provide an overview on the role of TS as a chemotherapeu-
tic target, the mechanism of TS translational autoregulation,
and the potential role of TS as a translational regulator of
other cellular genes with specific focus on p53. In its role as
an RNA binding protein, TS may act to coordinately
regulate the cellular expression of several genes, and in so
doing, may function as a critical regulator of several key
aspects of cell cycle control, apoptosis, and chemosensitiv-
ity.
2. Thymidylate synthase
TS plays an essential role in catalyzing the reductive
methylation of deoxyuridylate (dUMP) to thymidylate
(dTMP), which provides the sole intracellular de novo source
of dTMP (Fig. 1) [5]. Once synthesized, dTMP is then
metabolized intracellularly to the dTTP triphosphate form,
an essential precursor for DNA biosynthesis. This reaction is
critical as it maintains the essential metabolic requirements
for cellular proliferation and growth. As a result, TS repre-
sents a key target of cancer chemotherapeutic drugs, includ-
ing the fluoropyrimidines and various antifolate analogs
[6,7].
There are several lines of evidence which provide further
support to the concept that TS is an important chemother-
apeutic target. The first comes from in vitro, in vivo, and
clinical studies, which document a strong correlation
between the level of TS enzyme activity and/or TS protein
expression and response to fluoropyrimidines [8–10]. It has
been well-established that cancer cell lines and malignant
tumors expressing higher levels of TS are relatively more
resistant to the cytotoxic and antitumor effects of the fluo-
ropyrimidines and antifolate analogs targeting TS. Second,
there is a strong correlation between the level of TS enzyme
inhibition within patient tumor samples following 5-FU
therapy and eventual clinical response [11,12]. Third, the
higher response rates observed with the combination of 5-FU
and the reduced folate leucovorin (LV) when compared to
single-agent 5-FU provides support for the cell-free exper-
imental data which demonstrated that inhibition of the TS
enzyme was maximal in the presence of increasing concen-
trations of the reduced folate 5,10-methylenetetrahydrofolate
[13–17]. Finally, clinical trials with the antifolate analog
ZD1694, a specific inhibitor of TS, have revealed surpris-
ingly good activity as a single-agent against advanced color-
ectal cancer with response rates of 25–30%. These response
rates compare favorably with the combination of 5-FU and
LV. Based on these clinical results, this agent was approved
as first-line therapy for advanced, metastatic colorectal
cancer in several countries in Europe, Asia, Australia, and
Canada [18–20].
Fig. 1. Enzyme reaction catalyzed by TS.
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It is now well-established that regulatory events at the
level of gene amplification, transcription, post-transcription,
translation, and post-translation are all involved in control-
ling TS expression as it relates to cell cycle-directed events,
growth proliferation, and in response to various cytotoxic
agents (Fig. 2) [21–31]. There is growing evidence that the
precise control of TS may require multiple mechanisms
acting in close coordination with one another. Moreover,
there are several factors that must be taken into account,
including the specific cellular and/or genotoxic stress, the
timing and scheduling of exposure of a given cytotoxic agent,
the dose, and the specific cellular environment and model
system under investigation (Fig. 3).
The possibility for translational control of TS was postu-
lated by Belfort et al. [32] upon initial analysis of the
structural features of the E. coli TS thyA gene. In their cloning
and characterization of the human TS cDNA sequence,
Takeishi et al. [33] identified three tandem repeat sequences
in the 5V-untranslated region (UTR). Secondary structure
analysis predicted for the presence of a series of three
secondary stem-loop structures that might directly influence
TS mRNA translation. Further studies by Kaneda et al. [34]
confirmed that deletion of any one of these tandem repeat
sequences significantly altered the translational efficiency of
TS mRNA in vivo. These initial findings suggested that these
tandem sequences might regulate TS mRNA translation,
either directly or through their interaction with other cellular
proteins and/or cofactors.
Rapid increases in TS enzyme activity have been de-
scribed in various in vitro, in vivo, and clinical model systems
following short-term exposure to the fluoropyrimidines
[11,12,35–40]. While the precise mechanism(s) for the 5-
FU-induced expression of TS in response to 5-FU was not
well-characterized in these initial studies, increased tran-
scription, enhanced stability of TS mRNA, increased effi-
ciency of TS mRNA translation, and enhanced stability of TS
protein were all proposed as potential mechanisms. Signifi-
cant efforts have subsequently focused on defining the
molecular events that control this induction of TS.
Investigations by Keyomarsi et al. [41] using synchron-
ized normal human epithelial cells and human breast cancer
MCF-7 cells revealed a 40-fold increase in TS enzyme level
during the S phase with no apparent change in the level of TS
mRNA expression. They also showed that treatment ofMCF-
7 cells with the antifolate analog ZD1694 gave rise to a 10- to
40-fold increase in TS enzyme levels, as determined by the
FdUMP radioenzymatic binding assay, with no associated
alteration in TS mRNA levels [41]. Work from our own lab
showed that short-term, 24-h treatment of a human colon
cancer H630 cell line with 5-FU resulted in a 5.5- to 6-fold
elevation in TS protein expression with no corresponding
change in TS mRNA expression [42]. Subsequent work
revealed that the increased expression in TS protein was the
direct result of newly synthesized protein, thereby providing
the first direct evidence in vivo for the role of translational
regulation in controlling TS expression. Taken together, the
ability to regulate TS expression at the translational level may
provide (1) an important mechanism by which normal cel-
lular synthetic function can be precisely and tightly regulated,
and (2) a critical protective mechanism for the rapid develop-
ment of cellular resistance in response to exposure to a
cytotoxic stress such as 5-FU and/or ZD1694 in order to
maintain cellular synthetic function.
3. TS translational autoregulation
Since the regulation of TS expression during the cell cycle
and in response to exposure to various cytotoxic stresses
appears, in part, to be regulated by translational control, our
lab has focused on elucidating, in more detail, the regulation
of TS mRNA translation. Our current working model for TS
translational autoregulation and the interaction between TS
protein and its own TS mRNA is presented in Fig. 4. This
regulatory process is well-established as a critically impor-
tant mechanism controlling the expression of bacteriophage
and prokaryotic systems [43–47]. However, TS represents
the first eukaryotic gene whose expression is controlled in
such a fashion. The expression of three other eukaryotic
genes, including dihydrofolate reductase (DHFR) [48–50],
serine hydroxymethyl transferase [51], and p53 [52,53] have
now been shown to be controlled by a similar autoregulatory
feedback process.
Using a well-established RNA gel shift assay, we observed
that human recombinant TS was able to directly bind to its
own mRNA [54,55]. Subsequent work using the rabbit
reticulocyte lysate in vitro translation system revealed thatFig. 2. Molecular mechanisms regulating the expression of TS.
Fig. 3. Determinants of cellular gene expression.
J. Liu et al. / Biochimica et Biophysica Acta 1587 (2002) 174–182176
this TS protein–TS mRNA interaction resulted in transla-
tional suppression. Two cis-acting elements have been iden-
tified on TS mRNA, which interact with high affinity, on the
order of 1–3 nM, to TS protein [55]. The first site is a 30-nt
sequence residing in the 5V-UTR and includes the AUG start
site in the loop aspect of a stable stem-loop structure. The
secondary structure appears to be critical for protein recog-
nition as a series of mutations that abolished the stem-loop
resulted in RNA sequences that were unable to interact with
TS protein. The second site has recently been localized to a
70-nt sequence within the coding region corresponding to nt
480–550 [56]. In vivo studies using a luciferase reporter
system have confirmed the translational regulatory activities
of each element. While both sequences require the presence
of an intact TS protein and can function independently of one
another in vivo, both elements are required for complete
translational autoregulatory effect [56]. At present, it remains
somewhat unclear as to how binding of TS protein to the
sequence in the coding region leads to translational suppres-
sion. It is conceivable that some type of interactive cross-talk
occurs between the elements in the coding region and the 5V-
upstream region. A similar scenario has been observed with
sequences residing in the protein-coding region and the 3V-
UTR as playing a key role in controlling translational
initiation [57–60]. Detailed molecular modeling studies will
need to be performed to more precisely define the molecular
events controlling this very complex process.
In order to more fully characterize the molecular ele-
ments underlying the TS protein–TS mRNA interaction,
our lab has attempted to identify the specific domain(s) on
the TS protein that are required for RNA recognition. We
have shown that the RNA binding activity of human TS is
exquisitely sensitive to the presence of reducing agents and
requires the presence of at least one free sulfhydryl group
[61]. In the presence of increasing concentrations of either
2-mercaptoethanol or dithiothreitol, the RNA binding activ-
ity of TS was markedly increased. In contrast, treatment
with the oxiding agent diamide or N-ethylmaleimide
blocked RNA binding in a dose-dependent manner. Recent
preliminary work has shown that a cysteine! alanine
mutation at cysteine residue 180 completely eliminated
RNA binding. In contrast, mutations at cysteine residues
43, 195, and 210 did not adversely impact on RNA binding
activity. The precise mechanism(s) by which the cysteine
sulfhydryl residue at position 180 on the TS protein medi-
ates RNA binding remains to be more accurately defined.
However, several possibilities exist to explain its potential
central role. They include: (1) direct formation of a covalent
Michael adduct between the active sulfhydryl residue and
the C-6 position of a uracil ring on TS mRNA, (2)
occupation of the cysteine alters RNA binding via a steric
hindrance mechanism, and/or (3) the cysteine residue main-
tains the protein in a certain conformation that then allows
for the true RNA binding domain to be accessible. Studies
are currently in progress to determine which of these
mechanism(s) is involved.
In addition to the redox state of the protein, the state of
ligand occupancy of TS appears to play a key role as a
determinant of RNA binding [61]. For example, we have
shown that when TS is ligand-free, maximal RNA binding
activity is maintained, thereby resulting in complete trans-
lational repression of TS mRNA. In contrast, when TS is
bound by either its physiologic substrates, dUMP or 5,10-
methylentetrahydrofolate, or bound by the 5-FU metabolite
FdUMP or by an antifolate analog such as ZD1694, the
RNA binding activity of TS is dramatically decreased. The
net effect of reduced RNA binding activity is relief of
translational repression, a process that leads to increased
Fig. 4. Model for TS as a translational regulator of cellular gene expression.
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synthesis of new TS protein. Such a scenario would exist in
cells exposed to direct inhibitor compounds of TS, whether
they should be nucleotide analogs such as 5-FU or antifolate
analogs such as the Astra-Zeneca compound ZD1694 or the
Eli Lilly compound LY231514. Thus, this model provides a
rational mechanism for the acute induction of TS that arises
in response to exposure to TS inhibitor compounds. More-
over, it offers a novel mechanism for the development of
acute cellular drug resistance to compounds that directly
target TS.
4. TS as a translational regulator of cellular gene
expression
There are growing examples in the literature documenting
that a given RNA binding protein has the potential to interact
with more than one cellular mRNA species [62,63]. Perhaps
the best example is the iron-responsive factor (IRF), which
binds to its target iron-responsive element located within the
5V-UTRs of ferritin and erythroid 5-aminolevulinate synthase
mRNAs, and within the 3V-UTR of the transferrin receptor
mRNA [64,65]. The ability of the IRF to coordinately
regulate these different mRNAs allows for exquisite control
of iron metabolism within the cell. Based on this elegant
work, studies were undertaken in our lab to determine
whether TS, in its role as an RNA binding protein, might
be able to interact with other cellular RNAs. For these
studies, we developed a novel immunoprecipitation-RNA:
random polymerase chain reaction (rPCR) method to isolate
TS ribonucleoprotein (RNP) complexes from intact human
colon cancer H630 cells [66]. This technique was based on
the immunoprecipitation procedure of Steitz [67], and was
modified by incorporating the RNA:rPCR method of Frous-
sard [68]. Using this approach, we isolated eight different
cellular RNAs that formed a ribonucleoprotein (RNP) com-
plex with TS [66]. While TS was one of the RNAs identified
in this RNP complex, p53 and two members of the myc
family of transcription factors, c- and L-myc, were also
isolated. These specific mRNAs were of particular interest
as they play a critical role in cell cycle progression, DNA
synthesis, and apoptosis. Careful analysis of the eight RNA
sequences has, to date, failed to identify a consensus nucleo-
tide sequence. However, one potential drawback of such an
approach is that most of the RNA binding proteins, charac-
terized to date, appear to recognize a sequence contained
within the context of a stable secondary structure as opposed
to a simple sequence. In fact, there is preliminary evidence to
suggest the presence of such a consensus secondary structure
amongst these cellular mRNAs.
The critical role of p53 in tumor suppression, cell cycle
regulation, cell cycle arrest, and the cellular response to
DNA damage has been extensively reviewed [69–71]. The
mechanisms controlling the expression of p53, in response
to genotoxic and/or cytotoxic stress, are complex. Much of
the work performed to date has shown that the induction of
p53 following exposure to DNA-damaging agents is con-
trolled at the post-translational level, mainly through
enhanced stability of the protein [69,70,72]. It has been
well-established that post-translational modifications includ-
ing phosphorylation and acetylation at both the amino- and
carboxy-terminus are critical for activation of DNA binding
activity [73–75]. However, there is growing evidence that
translational control may play an important role in the
induction and activation of p53 in response to exposure to
cytotoxic agents [76]. For example, when murine fibroblast
Swiss 3T3 cells were exposed to g-irradiation, the expression
of p53 protein increased significantly while the correspond-
ing p53 mRNA levels were unchanged [52]. Treatment with
the transcriptional inhibitor actinomycin D did not alter the
induced levels of p53 protein, in contrast to treatment with
cycloheximide which completely repressed the induced syn-
thesis of p53. Subsequent investigations have confirmed that
the expression of p53 is controlled, in part, at the translational
level through an autoregulatory feedback loop identical to
what has been described for TS and DHFR [52,53]. One
element in the 5V-UTR of murine p53 mRNA has been
identified as a cis-acting target sequence for p53 protein,
while the essential cis-acting element for the human p53
mRNA has been localized to the 3V-UTR [77].
Because translational control appears to be at least one
mechanism governing p53 expression, and given our obser-
vation that a TS RNP complex composed of TS protein and
a sequence corresponding to the human p53 mRNA was
isolated from human colon cancer cells, further investiga-
tions were performed to confirm the interaction between TS
protein and p53 mRNA and to elucidate the potential bio-
logical consequences of such an interaction. Using a combi-
nation of RNA gel shift and in vitro translation assay
systems, we have shown that TS directly binds to a sequence
within the protein-coding region of p53 mRNA at the C-
terminal region [78,79]. The functional consequence of this
RNA–protein interaction is translational repression. These
studies have been extended to the in vivo setting to document
the biologic relevance of the TS protein–p53 mRNA inter-
action. As part of these studies, human colon cancer RKO
cells were transfected with the human TS cDNA under the
control of a tetracycline-inducible expression system. Treat-
ment of TS-transfected RKO cells with doxycycline (1 Ag/
ml), a tetracycline analog, resulted in a 15-fold induction of
TS protein, which was accompanied by a dramatic decrease
in the expression of p53 protein. Of note, no corresponding
change in p53 mRNA levels was observed. Immunoprecipi-
tation studies to isolate TS RNP complexes revealed a
significantly greater level of p53 mRNA bound to TS protein
in doxycycline-treated cells when compared to uninduced
cells. As a secondmodel system, we transfected TS-deficient,
parent HCT-C18 cells expressing a functionally inactive TS
with a human His-Tag TS cDNA under the control of a
constitutive CMV promoter. We have shown that p53 ex-
pression in these TS-transfected cells (HCT-C18:His-TS+)
was markedly decreased, and that this decreased p53 expres-
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sion was directly controlled at the translational level. These
TS-overexpressing cells were significantly impaired in the
their ability to arrest at either the G1/S or G2/M boundaries,
in response to g-irradiation and/or treatment with various
anticancer drugs including doxorubicin and 5-FU, when
compared to their corresponding parent HCT-C18 cells
[79]. In addition, the apoptotic response to drug exposure
was dramatically reduced in TS-overexpressing cells, as
evidenced by decreased activation of caspase-3 following
treatment with 5-FU. More recently, we have shown that TS-
overexpressing, HCT-C18:His-TS + cells are significantly
more resistant to TS inhibitor compounds such as 5-FU
and ZD1694, as well as to non-TS-related anticancer agents
such as doxorubicin and cisplatin by up to 4 -to 7-fold [80].
These observations lend support for the biological relevance
of the interaction between TS and p53 mRNA and suggest
that loss of p53 function through translational repression
results in an altered cell cycle checkpoint, in an altered
apoptotic response, and in the development of pleiotropic
drug resistance.
Taken together, these studies show that TS, in its capacity
as an RNA-binding protein, interacts with high affinity with
its own mRNA as well as with the mRNAs of the p53 tumor
suppressor gene. Thus, TS may be involved in the coordinate
regulation of expression and/or function of other genes.
Given the importance of p53 in the cell cycle and in main-
taining the requirements for cellular growth and prolifer-
ation, it is conceivable that TS may play an essential role as a
regulator of cell cycle-directed events. This may be espe-
cially relevant given the essential role of TS in providing the
requisite nucleotide substrates for DNA biosynthesis. Stud-
ies in our lab are currently focused on more precisely
defining the molecular elements mediating the interaction
between TS protein and the p53 mRNA, with emphasis on
defining the cis-acting elements on each of these mRNAs. In
addition, studies are in progress to determine whether the
same domain(s) is involved in binding of TS to its own
cognate TS mRNA as well as to other cellular mRNAs.
Finally, extensive efforts are being directed at elucidating the
downstream biological consequences of TS-mediated sup-
pression of p53 mRNA translation with specific emphasis on
cell cycle progression, cell cycle arrest, apoptosis, and che-
mosensitivity.
5. Discussion
In this review, we have highlighted the role of transla-
tional regulation as a mechanism for controlling the expres-
sion of TS. Moreover, we show that in addition to its critical
catalytic function, TS serves an important role as an RNA
binding protein. In this capacity, TS binds with high affinity
to its own mRNA and directly regulates its own biosynthesis
through a translational autoregulatory feedback mechanism.
Through its role as an RNA binding protein, it interacts with
several other cellular mRNAs including those corresponding
to the p53 tumor suppressor gene and the myc family of
transcription factors. In each of these cases, TS functions as
a translational repressor to coordinately regulate the expres-
sion and/or function of these important genes. Our studies
have shown that TS is able to serve as an effective trans-
lational regulator of cell cycle arrest, apoptosis, and chemo-
sensitivity.
6. Conclusions and perspectives
There are several issues that remain to be addressed regar-
ding the molecular basis for the interaction between TS and
its own TS mRNA, as well as with other cellular mRNAs. It
is clear that a more thorough understanding of the optimal
nucleotide sequences and/or secondary structures required
for protein recognition is needed. In addition, further work
will focus on more precisely defining the critical amino acids
and binding domain(s) on the TS protein that is needed for
RNA recognition. For sure, definitive characterization of
both the critical RNA binding domain(s) as well as the
essential nucleotide sequences and/or secondary structures
awaits the results of X-ray crystallography and/or NMR
analysis of the TS protein–TS mRNA complex. While these
structural studies have been limited, to date, by the avail-
ability of only small amounts of pure TS mRNA and human
TS protein, these technical limitations should be resolved in
the very near future.
One important issue to address relates to the intracellular
localization of the TS protein–TS mRNA complex as well as
the cellular localization of the other TS RNP complexes. For
this work, our lab is developing an in vivo fluorescence
immunohistochemistry approach. As a first step, we have
generated a series of deletional TS cDNA constructs with a
His-Tag placed at either the 5Vor 3Vterminus, and these
respective constructs have been transfected into human colon
cancer RKO cells. The intracellular localization of these
deletion proteins was compared with that of the wild-type,
full-length human TS protein [81]. Our studies, thus far, have
revealed that deletion of the first 10 amino acids at the
amino-terminus and deletion of 9 amino acids at the carboxy
terminus significantly altered cellular localization. Wild-
type, human TS protein was distributed uniformly through-
out the cell in both the nucleus and cytoplasm. In contrast,
the deleted TS proteins localized exclusively to the cyto-
plasm with absolutely no nuclear localization. Studies are in
progress to isolate the cellular location of TS mRNA using in
situ hybridization methods. Once these initial series of expe-
riments are performed, co-localization studies are planned to
determine the actual cellular location of the TS RNP com-
plex.
These molecular-based studies will expand our current
understanding of TS as an RNA binding protein and should
provide new insights into the role of TS as an important
regulator of certain critical aspects of cellular metabolism.
Moreover, such a detailed characterization of the interaction
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between TS and its own TS mRNA as well as with other
cellular RNAs may also serve as the rational basis for the
future development of novel therapeutic approaches.
There are several potential strategies that may arise from
such molecular-based studies as outlined in Fig. 5. For exam-
ple, identification of the specific RNA binding domain may
result in the development of novel inhibitors of TS enzymatic
activity that would still allow for formation of the TS
mRNA–TS protein complex in vivo. A stable ternary com-
plex composed of inhibitor, TS protein, and TS mRNA
might then result in marked suppression of new TS protein
synthesis. As an alternative approach, identification of the
putative RNA binding domain may lead to the development
of a small peptide that would then be used to target TS
mRNA and repress new TS protein synthesis. The use of
innovative modeling programs may identify small ‘‘de-
signer’’ molecules that mimic the structural features of the
binding peptide. Certainly, the potential advantage of such an
approach would be that novel organic molecules with
enhanced spatial and biophysical and biochemical properties
could be designed. Currently, this strategy is being taken in
anti-HIV drug development where small basic Rev and Tat
peptides that mimic the function of their corresponding
native proteins are being to tested for their ability to inhibit
HIV viral replication.
Identification of the consensus nucleotide sequence and/
or secondary structure containing the high affinity protein
binding site may lead to the design of an RNA oligonucleo-
tide that can be used to sequester and/or repress TS enzy-
matic function. An alternative strategy would be to design a
consensus nucleotide sequence/structure that might serve as
the target for either antisense- or ribozyme-based strategies
with resultant inhibition of TS protein synthesis. With this in
mind, our lab has recently showed that an 18-nt RNA
antisense molecule directed against the 5V-upstream cis-
acting element of TS mRNA can specifically inhibit TS
expression in human colon cancer RKO cells [82]. This
antisense oligoribonucleotide exerts its effects by inhibiting
TS mRNA translation, and in so doing, is able to inhibit
growth of the RKO cells with an IC50 concentration of 200
nM. However, one significant drawback to the use of nucleic
acids, whether it be RNA or DNA, is the inherent difficulty in
efficiently and specifically delivering them into their target
cells. The use of molecular modeling programs to design
small organic molecules that closely resemble the consensus
RNA sequence and/or structure may help to circumvent this
problem. Such compounds should then be delivered with
much greater efficiency and at relatively higher concentra-
tions into malignant cells than their nucleic acid counter-
parts. Several of these therapeutic approaches are now under
development in our lab in an attempt to bring more specific
and effective therapies into the clinic for the treatment of
human malignancies.
Acknowledgements
This work was supported by grants from the National
Cancer Institute (CA16359 and CA75712 to E.C.) and from
the Department of Veteran Affairs (VA Merit Review Award
to E.C.).
References
[1] M.B. Mathews, N. Sonenberg, J.W.B. Hershey, Origin and targets of
translational control, in: M.B. Mathews, N. Sonenberg, J.W.B. Her-
shey (Eds.), Translational Control, Cold Spring Harbor Press, Cold
Spring Harbor, NY, 1996, pp. 1–27.
[2] E.J. Brown, S.L. Schreiber, A signalling pathway to translational
control, Cell 86 (1996) 517–520.
[3] V.M. Pain, Initiation of protein synthesis in eukaryotic cells, Eur. J.
Biochem. 236 (1996) 747–771.
[4] M.J. Clemens, U.A. Bommer, Translational control: the cancer con-
nection, Int. J. Biochem. Cell Biol. 31 (1999) 1–23.
[5] C. Carreras, D.V. Santi, The catalytic mechanism and structure of
thymidylate synthase, Annu. Rev. Biochem. 64 (1995) 721–762.
[6] P.V. Danenberg, Thymidylate synthase: a target enzyme in cancer
chemotherapy, Biochim. Biophys. Acta 473 (1977) 73–79.
[7] L.W. Hardy, J.S. Finer-Moore, W.R. Montfort, M.O. Jones, D.V. Santi,
R.M. Stroud, Atomic structure of thymidylate synthase: target for ra-
tional drug design, Science 235 (1987) 448–455.
[8] P.G. Johnston, C.M. Liang, S. Henry, B.A. Chabner, C.J. Allegra,
Production and characterization of monoclonal antibodies that localize
thymidylate synthase in the cytoplasm of human cells and tissue,
Cancer Res. 51 (1991) 6668–6676.
[9] L. Leichman, K. Danenberg, J. Baranda, S. Groshen, W. Boswell, R.
Metzger, M. Tan, P.V. Danenberg, Quantitation of intratumoral thymi-
dylate synthase expression predicts for disseminated colorectal cancer
response and resistance to protracted-infusion fluorouracil and weekly
leucovorin, J. Clin. Oncol. 10 (1997) 3223–3230.
[10] H.J. Lenz, K. Hayashi, D. Salonga, K.D. Danenberg, P.V. Danenberg,
R. Metzger, D. Banerjee, J.R. Bertino, S. Groshen, L.P. Leichman,
C.G. Leichman, p53 mutations and thymidylate synthase messenger
RNA levels in disseminated colorectal cancer: an analysis of response
and survival, Clin. Cancer Res. 4 (1998) 1243–1250.
[11] S.M. Swain, M.C. Lippman, E.F. Egan, J.C. Drake, S.M. Steinberg,
C.J. Allegra, 5-Fluorouracil and high-dose leucovorin in previously
treated patients with metastatic breast cancer, J. Clin. Oncol. 7 (1989)
890–899.
Fig. 5. Development of novel therapeutic approaches to inhibit TS.
J. Liu et al. / Biochimica et Biophysica Acta 1587 (2002) 174–182180
[12] C.L. Van der Wilt, H.M. Pinedo, K. Smit, G.J. Peters, Elevation of
thymidylate synthase following 5-fluorouracil treatment is prevented
by the addition of leucovorin in murine colon tumors, J. Clin. Oncol.
12 (1994) 2035–2042.
[13] D.V. Santi, C.S. McHenry, H. Sommer, Mechanism of interaction of
thymidylate synthetase with 5-fluorodeoxyuridylate, Biochemistry 13
(1974) 471–480.
[14] K. Keyomarsi, R.G. Moran, Folinic acid augmentation of the effects
of fluoropyrimidines on murine and human leukemic cells, Cancer
Res. 46 (1988) 5229–5235.
[15] C. Erlichman, S. Fine, A. Wong, T. Elhakim, A randomized trial of
fluorouracil and foloiic acid in patients with metastatic colorectal
carcinoma, J. Clin. Oncol. 6 (1988) 469–475.
[16] M.A. Poon, M.J. O’Conell, C.G. Moertel, H.S. Wieand, S.A. Cullinan,
L.K. Everson, J.E. Krook, J.A. Mailliard, J.A. Laurie, L.K. Tschetter,
Biochemical modulation of fluorouracil: evidence of a significant im-
provement of survival and quality of life in patients with advanced
colorectal carcinoma, J. Clin. Oncol. 10 (1989) 1407–1418.
[17] Advanced colorectal cancer meta-analysis project. Modulation of flu-
orouracil by leucovorin in patients with advanced colorectal cancer:
evidence in terms of response rate, J. Clin. Oncol. 10 (1992) 896–903.
[18] D. Cunningham, J.R. Zalcberg, U. Rath, I. Oliver, E. van Cutsem, C.
Svensson, J.F. Seitz, P. Harper, D. Kerr Tomudex Colorectal Cancer
Study Group, Tomudex (ZD1694): results of a randomized trial in
advanced colorectal cancer demonstrate efficacy and reduced muco-
sitis and leucopenia, Eur. J. Cancer 12 (1995) 1945–1954.
[19] J.R. Zalcberg, D. Cunningham, E. van Cutsem, E. Francois, J. Scho-
magel, A. Adenis, M. Green, A. Iveson, M. Azab, I. Seymour,
ZD1694: a novel thymidylate synthase inhibitor with substantial ac-
tivity in the treatment of patients with advanced colorectal cancer, J.
Clin. Oncol. 14 (1996) 716–721.
[20] G. Cocconi, D. Cunningham, E. van Cutsem, E. Francois, B. Gustavs-
son, G. van Hazel, D. Kerr, K. Possinger, S.M. Hietschold, Open,
randomized, multicenter trial of raltitrexed versus fluorouracil plus
high-dose leucovorin in patients with advanced colorectal cancer, J.
Clin. Oncol. 16 (1998) 2943–2953.
[21] S.H. Berger, C.H. Jenh, L.F. Johnson, F.G. Berger, Thymidylate syn-
thase overproduction and gene amplification in fluorodeoxyuridine-
resistant human cells, Mol. Pharmacol. 28 (1985) 461–467.
[22] M.S. Copur, K. Aiba, J.C. Drake, C.J. Allegra, E. Chu, Thymidylate
synthase gene amplification in human colon cancer cells resistant to 5-
fluorouracil, Biochem. Pharmacol. 49 (1995) 1419–1426.
[23] L.G. Navalgund, C. Rossana, A.L. Muench, L.F. Johnson, Cell cycle
regulation of thymidylate synthase gene expression in cultured mouse
fibroblasts, J. Biol. Chem. 255 (1980) 7386–7390.
[24] C.H. Jenh, L.G. Rao, L.F. Johnson, Regulation of thymidylate syn-
thase enzyme synthesis in 5-fluorodeoxyuridine-resistant mouse fibro-
blasts during the transition from the resting to growing state, J. Cell
Physiol. 122 (1985) 149–154.
[25] C.H. Jenh, P.K. Geyer, L.F. Johnson, Control of thymidylate synthase
mRNA content and gene transcription in an overproducing mouse cell
line, Mol. Cell. Biol. 5 (1985) 2527–2532.
[26] D. Ayusawa, K. Shimizu, H. Koyama, S. Kaneda, K. Takeishi, T.
Seno, Cell-cycle-directed regulation of thymidylate synthase messen-
ger RNA in human diploid fibroblasts stimulated to proliferate, J.
Mol. Biol. 190 (1986) 559–567.
[27] Y. Geng, L.F. Johnson, Lack of an initiator element is responsible for
multiple transcriptional initiation sites of the TATA-less mouse thy-
midylate synthase promoter, Mol. Cell. Biol. 13 (1993) 4894–4903.
[28] S. Dong, L. Lester, L.F. Johnson, Transcriptional control elements and
complex initiation pattern of the TATA-less bidirectional human thy-
midylate synthase promoter, J. Cell. Biochem. 77 (2000) 50–64.
[29] Y. Ke, J. Ash, L.F. Johnson, Splicing signals are required for S-phase
regulation of the mouse thymidylate synthase gene, Mol. Cell. Biol.
16 (1996) 376–383.
[30] E. Chu, J.C. Drake, D.M. Koeller, S. Zinn, C.A. Jamis-Dow, G.C.
Yeh, C.J. Allegra, Induction of thymidylate synthase associated with
multidrug resistance in human breast and colon cancer cell lines, Mol.
Pharmacol. 39 (1991) 136–143.
[31] M.E. Kitchens, A.M. Forshoefel, Z. Rafique, H.T. Spencer, F.G. Berg-
er, Ligand-mediated induction of thymidylate synthase occurs by en-
zyme stabilization, J. Biol. Chem. 274 (1999) 12544–12547.
[32] M. Belfort, G. Maley, J. Pederson-Lane, F. Maley, Primary structure of
the Escherichia coli thyA gene and its thymidylate synthase product,
Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 4914–4918.
[33] K. Takeishi, S. Kaneda, D. Ayusawa, K. Shimizu, O. Gotoh, T. Seno,
Nucleotide sequence of a functional cDNA for human thymidylate
synthase, Nucleic Acids Res. 13 (1985) 2035–2043.
[34] S. Kaneda, K. Takeishi, D. Ayusawa, K. Shimizu, T. Seno, S. Altman,
Role in translation of a triple tandemly repeated sequence in the 5V
untranslated region of human thymidylate synthase mRNA, Nucleic
Acids Res. 15 (1987) 1259–1270.
[35] R. Labow, G.F. Maley, F. Maley, The effect of methotrexate on TS-
enzyme induced following partial hepatectomy, Cancer Res. 29 (1969)
366–372.
[36] R.J. Bonney, F. Maley, Effect of methotrexate on thymidylate synthe-
tase in cultured parenchymal cells isolated from regenerating rat liver,
Cancer Res. 25 (1975) 1950–1956.
[37] C.P. Spears, A.H. Shahinian, R.G. Moran, et al., In vivo kinetics of
thymidylate synthase inhibition in 5-fluorouracil-sensitive and -resist-
ant murine colon adenocarcinoma, Cancer Res. 42 (1982) 450–456.
[38] W.L. Washtien, Increased levels of thymidylate synthase in cells ex-
posed to 5-fluorouracil, Mol. Pharmacol. 25 (1984) 171–177.
[39] E. Chu, S. Zinn, D. Boarman, C.J. Allegra, Interaction of gamma-
interferon and 5-fluorouracil in the H630 human colon carcinoma cell
line, Cancer Res. 50 (1990) 5834–5840.
[40] S.J. Welsh, L. Titley, L. Brunton, M. Valenti, P. Monaghan, A.L.
Jackman, G.W. Aherne, Comparison of thymidylate synthase (TS)
protein up-regulation after exposure to TS inhibitors in normal and
tumor cell lines and tissues, Clin. Cancer Res. 6 (2000) 2538–
2546.
[41] K. Keyomarsi, J. Samet, G. Molnar, A.B. Pardee, The thymidylate
synthase inhibitor, ICI D1694, overcomes translational detainment of
the enzyme, J. Biol. Chem. 268 (1993) 15142–15149.
[42] E. Chu, D.M. Koeller, P.G. Johnston, S. Zinn, C.J. Allegra, Regulation
of thymidylate synthase in human colon cancer cells treated with 5-
fluorouracil and interferon-gamma, Mol. Pharmacol. 43 (1993) 527–
533.
[43] A. Bernardi, P.F. Spahr, Nucleotide sequence at the binding site for coat
protein on RNA of bacteriophage R17, Proc. Natl. Acad. Sci. U. S. A.
69 (1972) 3033–3037.
[44] J. Carey, V. Cameron, P.L. de Haseth, O.C. Uhlenbeck, Sequence-
specific interaction of R17 coat protein with its ribonucleic acid bind-
ing site, Biochemistry 22 (1983) 2601.
[45] M. Andrake, N. Guild, T. Hsu, L. Gold, C. Tuerk, J. Karam, DNA
polymerase of bacteriophage T4 is an autogenous translational re-
pressor, Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 7942–7946.
[46] L. Gold, Posttranscriptional regulatory mechanisms in Escherichia
coli, Annu. Rev. Biochem. 57 (1988) 199–203.
[47] G. Spedding, D.E. Draper, Allosteric mechanism for translational re-
pression in the Escherichia coli alpha operon, Proc. Natl. Acad. Sci.
U. S. A. 90 (1993) 4399–4403.
[48] E. Chu, C.H. Takimoto, D.M. Voeller, J.L. Grem, C.J. Allegra, Spe-
cific binding of human dihydrofolate reductase protein to dihydrofo-
late reductase messenger RNA in vitro, Biochemistry 32 (1993)
4756–4760.
[49] E. Ercikan, D. Banerjee, M. Waltham, B. Schnieders, K.W. Scotto,
J.R. Bertino, Translational regulation of the synthesis of dihydrofolate
reductase, Adv. Exp. Med. Biol. 338 (1993) 537–540.
[50] E.A. Ercikan-Abali, D. Banerjee, M.C. Waltham, N. Skacel, K.W.
Scotto, J.R. Bertino, Dihydrofolate reductase protein inhibits its own
translation by binding to dihydrofolate reductase mRNA sequences
within the coding region, Biochemistry 36 (1997) 12317–12322.
[51] X. Liu, B. Reig, I.M. Nasrallah, P.J. Stover, Human cytoplasmic serine
J. Liu et al. / Biochimica et Biophysica Acta 1587 (2002) 174–182 181
hydroxymethyltransferase is an mRNA binding protein, Biochemistry
39 (2000) 11523–11531.
[52] J. Mosner, T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, W.
Deppert, Negative feedback regulation of wild-type p53 biosynthesis,
EMBO J. 14 (1995) 4442–4449.
[53] L. Fu, M.D. Minden, S. Benchimol, Translational regulation of human
p53 regulation, EMBO J. 15 (1996) 4392–4401.
[54] E. Chu, D. Voeller, J.L. Casey, J.C. Drake, B.A. Chabner, P.C. El-
wood, S. Zinn, C.J. Allegra, Autoregulation of human thymidylate
synthase messenger RNA translation by thymidylate synthase, Proc.
Natl. Acad. Sci. U. S. A. 88 (1991) 8977–8981.
[55] E. Chu, D.M. Voeller, J.C. Drake, C.H. Takimoto, G.F. Maley, C.J.
Allegra, Identification of an RNA binding site for human thymidylate
synthase, Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 517–521.
[56] X. Lin, L.A. Parsels, D.M. Voeller, C.J. Allegra, G.F. Maley, F. Maley,
E. Chu, Characterization of a cis-acting regulatory element in the
protein coding region of thymidylate synthase mRNA, Nucleic Acids
Res. 28 (2000) 1381–1389.
[57] D.R. Gallie, The cap and poly (A) tail function synergistically to
regulate mRNA translation efficiency, Genes Dev. 5 (1991) 2108–
2116.
[58] R.J. Jackson, Cytoplasmic regulation of mRNA function: the impor-
tance of the 3Vuntranslated region, Cell 74 (1993) 9–14.
[59] V. Leathers, R. Tanguay, M. Koyayashi, D.R. Gallie, A phylogeneti-
cally conserved sequence within viral 3Vuntranslated RNA pseudo-
knots regulates translation, Mol. Cell. Biol. 13 (1993) 5331–5347.
[60] A.D. Ostareck-Lederer, D.H. Ostareck, N. Standard, B.J. Thiele,
Translation of 15-lipoxygenase mRNA is inhibited by a protein that
binds to a repeated sequence in the 3Vuntranslated region, EMBO J.
13 (1994) 1476–1481.
[61] E. Chu, D.M. Voeller, P.F. Morrison, K.L. Jones, T. Takechi, G.F.
Maley, F. Maley, C.J. Allegra, The effect of reducing reagents on
binding of thymidylate synthase protein to thymidylate synthase mes-
senger RNA, J. Biol. Chem. 269 (1994) 20289–20293.
[62] O.C. Uhlenbeck, H.N. Wu, J.R. Sampson, Recognition of RNA by
proteins, Molecular Biology of RNA, Academic Press, New York,
1987, pp. 285–294.
[63] O. Melefors, M.W. Hentze, Translational regulation by mRNA/protein
interactions in eukaryotic cells: ferritin and beyond, BioEssays 15
(1993) 85–90.
[64] R.D. Klausner, T.A. Rouault, J.B. Harford, Regulating the fate of
mRNA: the control of cellular iron metabolism, Cell 72 (1993) 19–28.
[65] B.R. Henderson, E. Menotti, C. Bonnard, L.C. Kuhn, Optimal se-
quence and structure of iron-responsive element, J. Biol. Chem. 269
(1994) 17481–17489.
[66] E. Chu, T. Cogliati, S.M. Copur, A. Borre, D.M. Voeller, C.J. Allegra,
S. Segal, Identification of in vivo target RNA sequences bound by
thymidylate synthase, Nucleic Acids Res. 24 (1996) 3222–3228.
[67] J. Steitz, Immunoprecipitation of ribonucleoproteins using autoanti-
bodies, Methods Enzymol. 180 (1989) 468–481.
[68] P. Froussard, rPCR: a powerful tool for random amplification of whole
RNA sequences, PCR Methods Appl. 2 (1992) 185–190.
[69] L.J. Ko, C. Prives, p53: puzzle and paradigm, Genes Dev. 10 (1996)
1054–1072.
[70] A.J. Levine, p53, the cellular gatekeeper for growth and division, Cell
88 (1997) 323–331.
[71] M.R.A. Mowat, p53 in tumor progression: life, death and everything,
Adv. Cancer Res. 74 (1998) 25–48.
[72] W. Maltzman, L. Czyzyk, UV irradiation stimulates levels of p53
cellular tumor antigen in nontransformed mouse cells, Mol. Cell. Biol.
4 (1984) 1689–1694.
[73] S.Y. Shieh, M. Ikeda, Y. Taya, C. Prives, DNA damage-induced phos-
phorylation of p53 alleviates inhibition by MDM2, Cell 91 (1997)
325–334.
[74] W. Gu, R.G. Roeder, Activation of p53 sequence-specific DNA bind-
ing by acetylation of the p53 C-terminal domain, Cell 90 (1997) 595–
606.
[75] K. Sakaguchi, J.E. Herrera, W. Saito, et al., DNA damage activates
p53 through a phosphorylation–acetylation cascade, Genes Dev. 12
(1998) 2831–2841.
[76] M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, R.W. Craig,
Participation of p53 protein in the cellular response to DNA damage,
Cancer Res. 51 (1991) 6304–6311.
[77] L. Fu, S. Benchimol, Participation of the human p53 3V-UTR in trans-
lational repression and activation following gamma-irradiation, EM-
BO J. 16 (1997) 4117–4125.
[78] E. Chu, S. Copur, J. Ju, T.M. Chen, S. Khleif, D.M. Voeller, N.
Mizunuma, M. Patel, G.F. Maley, F.Maley, C.J.Allegra, Thymidylate
synthase protein and p53 mRNA form an in vivo ribonucleoprotein
complex, Mol. Cell. Biol. 19 (1999) 1582–1594.
[79] J.F. Ju, J. Pederson-Lane, F. Maley, E. Chu, Regulation of p53 ex-
pression by thymidylate synthase, Proc. Natl. Acad. Sci. U. S. A. 96
(1999) 3769–3774.
[80] J. Ju, E. Chu, Translational regulation of 5-FU-induced p53 expression
in human cancer RKO cell, Proc. Am. Assoc. Cancer Res. 41 (2000)
854, 5422a.
[81] J. Liu, X.K. Lin, F. Gorelick, F. Maley, E. Chu, Sequence require-
ments for the intracellular localization of human thymidylate synthase,
Proc. Am. Assoc. Cancer Res. 43 (2002) 100, 502a.
[82] J.C. Schmitz, D. Yu, S. Agrawal, E. Chu, Effect of 2V-O-methyl anti-
sense ORNs on expression of thymidylate synthase in human colon
cancer RKO cells, Nucleic Acids Res. 29 (2000) 415–422.
J. Liu et al. / Biochimica et Biophysica Acta 1587 (2002) 174–182182
